Jonestrading initiated coverage on shares of HCW Biologics (NASDAQ:HCWB – Get Rating) in a research note published on Monday, The Fly reports. The brokerage issued a buy rating and a $8.00 price target on the stock.
HCW Biologics Trading Down 3.0 %
Shares of HCW Biologics stock opened at $2.25 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 30.24 and a current ratio of 12.52. HCW Biologics has a 12-month low of $1.76 and a 12-month high of $3.32. The firm's 50 day simple moving average is $2.33 and its two-hundred day simple moving average is $2.28.
Get
HCW Biologics alerts:
HCW Biologics (NASDAQ:HCWB – Get Rating) last issued its earnings results on Friday, August 12th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $0.45 million for the quarter.
Insiders Place Their Bets
In other news, CFO Rebecca Byam bought 50,000 shares of HCW Biologics stock in a transaction on Wednesday, August 24th. The shares were bought at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the acquisition, the chief financial officer now owns 205,452 shares in the company, valued at $513,630. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at
this hyperlink. In the last ninety days, insiders have purchased 104,000 shares of company stock worth $265,230. Corporate insiders own 44.00% of the company's stock.
Institutional Investors Weigh In On HCW Biologics
An institutional investor recently raised its position in HCW Biologics stock. HighTower Advisors LLC raised its stake in shares of HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) by 2,056.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 215,598 shares of the company's stock after acquiring an additional 205,598 shares during the quarter. HighTower Advisors LLC owned approximately 0.60% of HCW Biologics worth $588,000 at the end of the most recent quarter. 1.59% of the stock is owned by institutional investors and hedge funds.
About HCW Biologics
(Get Rating)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
